Targeting LRRK2 in Parkinson’s disease

Jennings et al.(1) reported that LRRK2 inhibitors can reduce kinase activity and improve lysosomal function with minor adverse effects in both animal models and human subjects. The findings provide proof of principle for LRRK2 inhibitor as a Parkinson’s disease therapeutic option.

Detalles Bibliográficos
Autores principales: Xiao, Bin, Tan, Eng-King
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589013/
https://www.ncbi.nlm.nih.gov/pubmed/36260987
http://dx.doi.org/10.1016/j.xcrm.2022.100778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589013/
https://www.ncbi.nlm.nih.gov/pubmed/36260987
http://dx.doi.org/10.1016/j.xcrm.2022.100778

Ejemplares similares